gh tesa ipa cjc blend
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 1 mg | 5 days on, 2 off | — |
| Intermediate | 1.5 mg | 5 days on, 2 off | AM & PM |
| Advanced | 2 mg | 5 days on, 2 off | — |
| Maximum | 2 mg 2x/day | 5 days on, 2 off | — |
Blend Dosing Approach
This **pre-combined formulation** provides a fixed ratio of all three peptides in a single injection, eliminating the complexity of preparing and timing multiple separate compounds. The blend is administered via **subcutaneous injection** with dosing determined by volume rather than individual peptide amounts, since the concentrations are predetermined in the formulation. Given that all three components work through **growth hormone axis activation**, they can be administered together without timing conflicts. The **pharmacokinetic profiles** complement each other, with tesamorelin providing longer-duration effects while ipamorelin and CJC-1295 (No DAC) contribute to maintaining **physiological pulsatility**. This approach simplifies administration while potentially providing more comprehensive GH axis stimulation than individual peptides used separately.
Per-Component Breakdown
Synergy Rationale
This blend strategically combines three **complementary growth hormone axis modulators** that work through different but synergistic mechanisms. **Tesamorelin** provides sustained GHRH receptor activation with proven efficacy in **visceral fat reduction**, while **CJC-1295 (No DAC)** maintains **physiological GH pulsatility** through its shorter duration of action. **Ipamorelin** adds **selective ghrelin receptor activation** without unwanted cortisol or prolactin elevation, providing additional GH stimulation through a distinct pathway. The combination leverages both **GHRH and ghrelin receptor pathways** simultaneously, potentially creating more robust growth hormone release than either approach alone. Tesamorelin's established clinical efficacy in **targeted fat loss** is complemented by the body composition benefits associated with the other peptides. The varying **pharmacokinetic profiles** - from tesamorelin's longer effects to ipamorelin's rapid clearance - may provide both immediate and sustained GH stimulation throughout the dosing interval.
Combined Mechanism
The three peptides create a **multi-pathway approach** to growth hormone axis activation, targeting different receptors and signaling cascades simultaneously. **Tesamorelin and CJC-1295** both activate **GHRH receptors** on pituitary somatotrophs, triggering **adenylyl cyclase and cAMP-dependent pathways** that stimulate GH transcription and release. **Ipamorelin** provides complementary stimulation through **ghrelin receptor (GHSR-1a) activation**, utilizing **Gq/11 signaling and calcium mobilization** pathways. This dual-receptor approach may produce more robust and sustained **GH elevation** than single-pathway stimulation. All three compounds preserve **pulsatile GH release patterns**, maintaining natural feedback mechanisms while potentially amplifying the overall response. The downstream effects converge on **IGF-1 production** and the subsequent activation of **PI3K/Akt and MAPK signaling pathways** in target tissues. This coordinated stimulation supports multiple benefits: **enhanced lipolysis** (particularly visceral fat through tesamorelin's proven mechanism), **protein synthesis** via mTOR pathway activation, and **metabolic optimization** through improved insulin sensitivity. The combination may also provide **synergistic effects** on recovery and body composition through complementary receptor activation patterns.
Research Context
While extensive research exists on each individual peptide, **direct studies of this specific three-peptide combination are limited**. Most research has focused on individual compounds or two-peptide combinations rather than this particular triple blend. However, the scientific rationale for combining **GHRH analogs with ghrelin receptor agonists** is supported by studies showing that different GH secretagogue pathways can work synergistically. Research on similar **multi-peptide approaches** in growth hormone therapy suggests potential benefits of targeting multiple pathways simultaneously. The combination leverages well-established individual mechanisms, but **specific clinical data on this exact formulation** remains limited. Current understanding is based primarily on the known pharmacology of each component and theoretical synergies rather than dedicated combination studies. This represents an area where **additional research** would be valuable to fully characterize the combined effects.
Research Use Only: All compounds discussed on this page are intended for laboratory research purposes only. Not for human consumption. All research should be conducted in compliance with institutional guidelines and applicable regulations. Consult qualified healthcare professionals before making any decisions regarding compound research or use.
Tesamorelin / CJC-1295 / Ipamorelin
Quick Reference
- Default Dose
- 1 mg
- Frequency
- 5 days on, 2 off
- Timing
- AM
- Dilution
- 1 ML
For Practitioners
Interested in offering research-grade compounds through your practice? Learn about our affiliate program for qualified practitioners.
Find a ProviderPractitioner Information